Dual endovascular filter and methods of use

Information

  • Patent Grant
  • 11191631
  • Patent Number
    11,191,631
  • Date Filed
    Wednesday, November 7, 2018
    5 years ago
  • Date Issued
    Tuesday, December 7, 2021
    2 years ago
Abstract
A removable dual endovascular filter that may be introduced into arteries of the heart during surgery to allow sufficient blood flow to a cerebral vascular system while minimizing or preventing embolic material from traveling throughout a body circulatory system. The removable dual endovascular filter reduces the risk of stroke while minimizing obstruction of the patient's aorta.
Description
INCORPORATION BY REFERENCE

All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.


BACKGROUND OF THE INVENTION

Endovascular procedures are being used more and more frequently to treat various cardiac and vascular surgical problems. Blocked arteries can be treated with angioplasty, endarterectomy, and/or stenting, using minimally invasive endovascular approaches. Aneurysms can be repaired by endovascular techniques. Another use for endovascular surgery is the treatment of cardiac valvular disease. A common problem in endovascular catheterization is that plaque found in the diseased vessels and valves can be dislodged and result in embolization. A major drawback to endovascular treatment of cardiac valves and arteries in the heart or thoracic aorta is that the dislodged debris can embolize into the carotid vessels resulting in catastrophic consequences such as stroke or even death. Attempts have been made to protect the cerebral vasculature with filters and other devices, but the inadequacy of the present art is obvious in the fact that these devices are rarely used. The pending patent applications for such protection devices suggests both the inadequacy of the present art and the need for improved devices not to deflect the emboli but to capture and remove the emboli from the body.


The majority of devices described are filters. The problems with filters include difficulty in placement and retrieval as well as the possibility that a filter will fill abruptly causing blockage of the artery prior to removal of the filter. Cerebral protection requires placement of filters in the carotid arteries, which has the additional drawback of manipulation of the carotid vessels during filter placement while the cerebral vasculature is still unprotected. The risk of stroke for a carotid arteriogram done by cannulation of the carotid artery is 1% compared to an arteriogram done from injection into the aorta without selective cannulation which carries minimal risk. The risk of cannulating a carotid artery, navigating a catheter containing a filter into position, and deploying the filter would likely carry an even higher stroke risk. Patients requiring cardiac or aortic arch procedures are high risk candidates for having carotid disease. The chance of causing a stroke by the placement of the protective device into both carotid arteries makes the risk of using these devices prohibitive. The time and skill necessary to selectively cannulate both carotid arteries for filter placement has also contributed to the decision not to use them despite the stroke risk of unprotected cardiac and aortic arch procedures.


BRIEF DESCRIPTION OF THE INVENTION

The present invention comprises an embolic filter device. In use, the invention is placed into the aortic arch by the access via right-radial or brachial entry, preferably through the right arm but it may also be placed via the femoral artery or other access point used by interventional procedures such as the carotid artery. In one embodiment, the device is deployed partially in the aortic arch but also in the innominate artery and carotid artery. Additionally or alternatively, the device may deploy to protect the left subclavian artery, where the device is opened and pulled back into position to cover the ostia of both the brachiocephalic and left common carotid arteries. A portion of the device, typically extending from a common hinged frame protrudes into the vessel(s) with a portion of the device entering into the vessel or artery to trap emboli. In some embodiments the portion of the device arising from the common frame has a cone, funnel or other shape adapted or configured for positioning within the vessel lumen to filter emboli.





BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of the invention are set forth with particularity in the claims that follow. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative 30 embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:



FIG. 1 depicts a schematic version of the filter device extending from the delivery catheter.



FIG. 2 depicts the filter device delivered and protecting the innominante artery and the left common carotid artery with the self-expanding frame and the dome filter material protruding into each vessel.



FIG. 3 depicts the device being closed and capturing the embolic material within each dome filter.



FIG. 4 depicts the domes closed at a common hinge point to trap the embolic material within the filter and ready to be withdrawn from the body.



FIG. 5 depicts the filter device being drawn back into the catheter ready to be removed from the body.



FIG. 6 illustrates a filter positioned within the aorta and connected to a locking device (unlocked configuration).



FIG. 7 illustrates the filter of FIG. 6 after tensioning the filter into a sealing arrangement within the aorta and protected vessels and restraining the filter with the locking device (locked configuration).



FIG. 8 illustrates a variety of exemplary shapes, sizes, and configurations of holes that can be formed in one or more of the filters.





DETAILED DESCRIPTION OF THE INVENTION

In one embodiment, filter device 100 of the present invention is positioned prior to any manipulation of the heart or thoracic aorta. FIG. 1 illustrates the filter device 100. The filter device 100 includes a frame 105 having a hinge or collapsible joint 110. The frame 105 has a generally circular shape that contains two filter portions 115, 130. The filter portions 115, 130 extend out of plane with the frame 105 into shaped sections 120, 135. The size, shape and filter characteristics of the filters 115, 130 and shaped sections 120, 135 may vary based on a number of factors such as the size, shape and relative position of the one or more vessels to be protected by the device 100 as well as the particle size selected for filtration and the desired amount of blood flow through the filter 100. These and other details of the component parts, various embodiments and uses for embodiments of the filter 100 are described below.


The device 100 is simple to place and carries only the risk of catheterizing the aorta through the arm or leg, which is minimal. In use as shown in FIG. 2, the device is opened in the thoracic aorta and positioned to cover the ostia of both the inominant and left common carotid arteries and at least a portion of the device will partially enter the inominant and left common arteries. In the illustrated embodiment all or a portion of the shaped sections 120, 135 are within the protected vessel or vessels. This position prevents clots or debris from entering the cerebral circulation through either the right or left carotid arteries with one simple device. Any debris from the cardiac or aortic procedure is captured in the paraboloid of revolution shape 120, 135 protruding into each vessel from the filter 100.


After the procedure is complete, the device is inverted by means of a sheath 50 extended over the catheter wire 102, which then wholly or partially covers the inverted device prior to withdrawal. As shown in FIGS. 3, 4 and 5, should any clot or debris be captured in the paraboloid of revolution 120, 135, the clot or debris will be captured when inverted via common hinge point 110 and withdrawn along with the device 100. The protrusion or depth of vessel entry of the shaped sections 120, 135 into each of the vessels may vary depending upon a number of factors such as expected particle or emboli size, amount or interaction with the filter 100. In one specific example, the shaped section portion of the filter extends from about 0.5 centimeters to about 3.0 centimeters measured from the device frame 105 positioned in the aorta. The material 115, 130 protruding into the vessel could be any suitable vascular filter material. For example, filters 115, 130 may be formed from, with or contain a polymeric material such as polyurethane with drilled holes for blood flow to the cerebral vasculature. In one aspect, the drilled holes could measure about 100 to 200 microns in diameter but preferably about 130 microns in diameter. Alternatively, the filters 115, 130 may be formed from porous material suited to trapping emboli. The material for filters 115, 130 is selected to allow for adequate filtration where the porous or drilled or formed openings will allow for sufficient blood supply to the cerebral vascular system while stopping any embolic material from traveling throughout the body circulatory system. Trapping and removal of embolic particles within filters 115, 130 rather than merely deflecting material into the aorta is believed to provide a better clinical outcome for the patients. Embolic particles simply deflected back into the aorta will eventually block other blood vessels elsewhere in the body such as the kidneys or lower extremities. As such, embodiments of the device 100 may advantageously be employed to filter out, capture and then remove emboli while also keeping the aorta relatively clear. As best seen in FIG. 2, the frame 110 only remains in the aorta since the filters 115, 130 extend substantially above the plane of frame 105.


The device is preferably concaved-shape with an adequate area to cover the ostia of both the brachiocephalic and left common carotid arteries (FIGS. 1 and 2). The filters 115, 13030 may be made of a material with pores (100 to 200 micron) or similar openings or permeability to allow the flow of blood into the cerebral circulation, but able to deflect or trap particles of a size which could cause a stroke. The edge of the frame 105 is preferably a flexible, porous donut shape allowing a good seal with the curved aortic wall. In some embodiments, the edge of the frame 105 will preferably contain a nitinol wire ring or other self-expanding material. The device may have struts or ribs positioned on, in or within frame 105 to assist in the opening and closing of the device and to help maintain its position in use. The device may also be made to open as a result of its construction material, for example, nitinol or polymer, elastically resuming its shape after being released from its sheath.


When the device is to be closed, a tube or sheath is extended over the guide wire until it engages the device. Next, the device is pulled back so that it inverts and is enclosed in the tube for removal (FIGS. 3 and 4). Inverting the device so that the filter openings for each of the filters 115, 130 assures that no trapped particles within filters 115, 130 such as within shaped sections 120, 135 escape into the bloodstream. The components of the device 100 may optionally be 10 constructed of polymer, fabric, metal, or a combination of these or other suitable biocompatible materials. The device may also optionally be equipped with radio-opaque markers or other structural parts which are radio-opaque for aid in placement guidance and/or positioning within the body.


Another embodiment of the device has a rolled edge.


The device may also have a flat porous edge.


Another embodiment of the device has no struts, but instead has a nitinol skeleton.


Another embodiment has multiple wires to position and anchor the device.


Another embodiment of the device has anchors at the edges which help to maintain its position during the procedure.


Another embodiment of the device is parachute-like, with a ring gasket at its edge. The gasket can be a softer material such as, for example without limitation, a silicone polymer or an inflatable membrane such as a balloon member. The profile of an inflatable gasket is generally relatively small and when inflated increases in profile, sealing the contacted portion surrounding the protected vessels. The inflation can be pressurized from the handle portion at the proximal end of the device external to the body with, for example a common endoflator used in interventional cardiology. The gasket would be held firmly in position over the ostia of the brachiocephalic and left common carotid arteries. The billowy porous middle section would deflect or trap clot and debris on its exterior surface while causing minimal resistance in the aorta. The middle portion would be inverted as it is removed by pulling on wires attached to its center, capturing any clot stuck to it.


Alternatively, the center of the device may comprise a screen, which fits more snugly against the aortic wall, with a very small profile, further preventing resistance to downstream aortic bloodflow. Again the device would be removed by inversion, capturing any debris stuck to it prior to removal.


The device may be round, oval or rectangular or of another shape to assist in sealing of the edge against the wall of the aorta, covering the ostia of both the brachiocephalic and left common carotid arteries and maintaining a low profile within the lumen of the aorta.


This device could be modified in size in another embodiment in order to be used to 5 cover the ostia of different vessels.


The device may be coated with materials or pharmalogically active agents that prevent or impair clot formation (e.g., heparin or any other suitable anticoagulant).


The device may be deployed through an artery of the arm, or through the femoral artery. The preferred method would be through the right arm, if possible, as this would allow the device to be pulled back against the aortic wall to place it.


When deployed through the femoral artery, the opening of the device would be different and the device would be pushed against the aortic wall over the brachiocephalic and left common carotid openings rather than being pulled back. A wire would be cannulated into the brachiocephalic artery in this case to ensure correct positioning of the device. The device would be modified to allow this method of delivery and positioning. In one aspect, retrieval of the device would involve inversion and closing of the device by drawstring or another method. For example, pulling, activating, manipulating or otherwise causing movement of the common hinge or frame joint 110.


Brachial Artery Insertion of the Device


The device is delivered via percutaneous insertion into the right brachial artery and is guided into the aortic arch. There it is deployed and then pulled back into position to cover the ostia of the innominate and left common carotid arteries. The device deflects and filters embolic debris during aortic and cardiac procedures, allowing the flow of blood through into the cerebral circulation (carotid arteries) but not permitting the passage of particulate debris.


Femoral Artery Insertion of the Device


The device is delivered via percutaneous insertion into the femoral artery and is guided into the aortic arch. After catheterization of the innominate artery, the device is passed 30 over the wire and brought into position covering the ostia of the innominate and left common carotid arteries.


Deployment of the Device via Arm Approach


Percutaneous access to the circulation via the right arm is performed and a wire guided into the aortic arch after exiting the innominate artery. The device may be placed over the wire or advanced without a guidewire and guided into the aortic arch. The covering outer sheath which encapsulates the device is retracted, exposing the device to the aortic bloodstream. The device is then opened in the aortic arch. The device is pulled back into position, covering the ostia of the innominate and left common carotid artery with a portion of the device entering into each vessel. The device allows the passage of blood through to the carotid arteries, but deflects debris passing along the aorta and filtering any embolic material entering the innominante and left common carotid arteries. At the completion of the debris producing concomitant procedure, the device is closed by inverting the two domes 120, 135. The device is then withdrawn into a covering sheath (FIG. 5) to completely encapsulate it prior to removal from the arm access artery. Any trapped debris is captured in the domes, safely and securely within the catheter.


Embolic Filteration Device


The device of the present invention, viewed from above, is semi-circular or oval in shape with an adequate diameter of about 15 mm to about 30 mm in the short axis and about 20 mm to about 60 mm in the long axis to cover the ostia of both the brachiocephalic and left common carotid arteries. The filter material may be a polymeric material such as polyurethane or other thin material with a porosity that will allow the flow of blood, but capture particles of a size which could cause a stroke. FIG. 8 illustrates exemplary sizes, shapes, and configuration of the holes that can be formed in a filter. The size and configuration of the holes in the filter could be round in shape but more effectively would be an oval or a slot configuration where the material captured would be smaller but the surface area of the openings could be larger. Other shapes could include triangular or squares to achieve the same function. A square hole would provide about 30 percent more cross sectional area for blood to flow while still capturing the same spherical particle size. The edge of the device is a flexible, porous donut, similar to the edge of a diaphragm, allowing a good seal with the curved aortic wall. The edge will preferably contain a self-expanding material such as Nitinol. The frame of the device may also include struts to assist in the opening and closing of the device and/or to help maintain its position in the relevant anatomy.


The device is constructed of polymer, fabric, metal, or a combination of these materials. The device may be provided with radioopaque markers or metal parts which are radioopaque.


Another embodiment of the device has a rolled edge. The device could also have a flat porous edge. Another embodiment of the device has no struts, but a nitinol skeleton. Another embodiment has multiple wires to position and anchor the device. Another embodiment of the device has anchors at the edges which help to maintain its position during the procedure.


Another embodiment of the device is parachute-like, with a ring gasket at its edge. 5 The gasket would be held firmly in position over the ostia of the brachiocephalic and left common carotid arteries.


Embodiments of the filter 100 may be configured for self locking and/or self sealing with or within the anatomy of the filter site. Self lock or self sealing may be accomplished by releasing a stowed filter from a sheath or other restraint or otherwise activity or actuating the device into a locked or sealing configuration.


Alternatively, the filter may be released into the vasculature and then urged into a locked or sealed configuration. In one aspect, a locking device is positioned outside the body that is adapted and configured to permit movement of or adjusted to the filter relative to the filter site to seal and/or lock the position and configuration of the filter. When the desired position and configuration is achieved the external locking device is used to hold the filter in position and maintain the desired configuration.


In one specific aspect, once the desired filter device position is obtained, a locking mechanism 52 relative to the body could hold tension between the device and the aortic wall to maintain a proper blood seal. This could be achieved by tensioning the connection of the device within the body via delivery catheter and a clamp or fixation device between the introducer sheath and tensioned member. A good example of this would be a RHV (rotating hemostaic valve) mounted to the introducer sheath allowing the tensioned connection member to pass through the central lumen. As the tension is added to the central member the RHV could be rotated causing an interference force between the two creating a lock where the tension is now carried by the introducer sheath which is external to the body and the internal filter device which is held in tension along the aortic wall without constant human interaction pulling the device relative to the introducer sheath now needed. Turning now to the example of FIGS. 6 and 7. FIG. 6 illustrates the filter deployed within the aorta but not yet sealed with the anatomy. A locking mechanism 52, here a rotating hemostasis valve, is used to allow movement between and lock the relative position of the element connected to the filter (i.e. a guidewire) and the sheath used to deliver the filter. After pulling the filter into a sealing arrangement with the appropriate vessels, the RHV may be locked thereby securing the filter relative to the sheath and the entire device relative to the anatomy. The RHV in the illustrative embodiment may be replaced by any suitable locking device that provides the adjustment, sealing and securing characteristics described above.


The billowy porous middle section would deflect or trap clot and debris on its exterior surface while causing minimal resistance in the aorta. The middle portion would be inverted as it is removed by pulling on wires attached to its center, capturing any clot stuck to it. Alternatively, the center of the device could be a screen, which fits more snugly against the aortic wall, with a very small profile, further preventing resistance. Again the device would be removed by inversion, capturing any clot stuck to it prior to removal.


The device may be round, oval or rectangular or of another shape to assist in sealing of the edge against the wall of the aorta, covering the ostia of both the brachiocephalic and left common carotid arteries and maintaining a low profile within the lumen of the aorta. This device could be modified in size in another embodiment in order to be used to cover the ostia of different vessels. The device may be coated with something which prevents clots (e.g. heparin).


Any of the features of the filter devices and methods of use described herein can be incorporated into any of the filter devices and methods of use described in U.S. Patent Publication No. 2010/0179647, U.S. Patent Publication No. 2010/0179585, U.S. Patent Publication No. 2010/0179584, U.S. Patent Publication No. 2010/00179583, and U.S. Patent Publication No. 2008/0065145 (and vice versa), all of which are incorporated by reference herein. For example, the disclosure herein includes embodiments in which the emboli deflection element from the Patent Applications recited above is replaced with first and second emboli trapping filters, examples of which are described herein.


While the invention has been described in its preferred embodiments, it is to be understood that the words which have been used are words of description rather than of limitation and that changes may be made within the purview of the appended claims without departing from the true scope and spirit of the invention in its broader aspects. Rather, various modifications may be made in the details within the scope and range of equivalents of the claims and without departing from the spirit of the invention. The inventor further requires that the scope accorded the claims be in accordance with the broadest possible construction available under the law as it exists on the date of filing hereof (and of the application from which this application obtains priority, if any) and that no narrowing of the scope of the appended claims be allowed due to subsequent changes in the law, as such a narrowing would constitute an ex post facto adjudication, and a taking without due process or just compensation.

Claims
  • 1. An embolic filter device, comprising: a sheath;a hinged frame including a first frame segment and a second frame segment joined along a common hinge joint, the hinged frame having a delivery configuration, a deployed configuration, a first recovery configuration, and a second recovery configuration, and wherein each of the first frame segment and the second frame segment may be generally circular, semi-circular, oval, round or rectangularly shaped;wherein the hinged frame comprises: a first filter portion and a second filter portion, each extending out of a plane of the hinged frame,wherein the first filter portion is secured to the first frame segment of the hinged frame and the second filter portion is secured to the second frame segment of the hinged frame,wherein the first filter portion and the second filter portion each have an open end and a closed end,wherein each closed end is adapted to trap foreign particles therein,wherein in the first recovery configuration, the first frame segment and the second frame segment are parallel and the open end of the first filter portion and the open end of the second filter portion are opposed,wherein in the delivery configuration the hinged frame is contained within the sheath, andwherein in the deployed configuration, the hinged frame is configured to engage a wall of an aorta in a vicinity of and spanning ostia of a brachiocephalic artery and a left common carotid artery and the first filter portion and the second filter portion are concave shaped and extending out of the plane of the hinged frame on a same side of the hinged frame.
  • 2. The embolic filter device of claim 1, further comprising an elongate delivery member attached to the hinged frame proximate the common hinge joint.
  • 3. The embolic filter device of claim 1, wherein the first filter portion extends about 0.5 cm out of the plane of the hinged frame.
  • 4. The embolic filter device of claim 1, wherein the second filter portion extends about 3 cm out of the plane of the hinged frame.
  • 5. The embolic filter device of claim 1, wherein the first filter portion and the second filter portion substantially have forms of paraboloids of revolution.
  • 6. The embolic filter device of claim 1, wherein the sheath further comprises a lock to lock the hinged frame relative to the sheath.
  • 7. The embolic filter device of claim 6, wherein the lock is configured and adapted to lock the sheath in a position relative to a patient when the embolic filter device is positioned within a patient.
  • 8. The embolic filter device of claim 1, wherein the first frame segment of the hinged frame and the second frame segment of the hinged frame are adapted to fold toward each other along the common hinge joint to attain the first recovery configuration.
  • 9. The embolic filter device of claim 1, wherein the embolic filter device is configured and adapted to assume the first recovery configuration before assuming the second recovery configuration.
  • 10. The embolic filter device of claim 1, wherein the first filter portion and the second filter portion each include a plurality of openings through the wall thereof that are sized and shaped to allow sufficient blood flow to a cerebral vascular system while preventing embolic material from traveling throughout a body circulatory system.
  • 11. The embolic filter device of claim 10, wherein at least some of the plurality of openings include openings having noncircular shape.
  • 12. The embolic filter device of claim 10, wherein at least some of openings include openings having more than one shape.
  • 13. The embolic filter device of claim 10, wherein at least some of the plurality of openings include openings having more than one size.
  • 14. The embolic filter device of claim 13, wherein the first filter portion includes a first plurality of openings having a first size and a second plurality of openings having a second size wherein the first size is different from the second size.
  • 15. The embolic filter device of claim 1, wherein when the hinged frame is in the first recovery configuration the first frame segment and the second frame segment are configured to close and trap particles within the first filter portion and the second filter portion.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 14/644,083, filed Mar. 10, 2015, which is a continuation of U.S. application Ser. No. 13/383,488 filed Mar. 23, 2012, now issued as U.S. Pat. No. 8,974,489, which a continuation of a national stage application under 35 U.S.C. § 371 of PCT Application No. PCT/US2010/043390, filed on Jul. 27, 2010, which published in English as WO 2011/017103 A2 on Feb. 10, 2011 and which claims priority benefit of U.S. Provisional Application No. 61/228,703, filed Jul. 27, 2009, entitled “Dual Endovascular Filter and Methods of Use,” the entire contents of which applications and publication are herein incorporated by reference in their entirety.

US Referenced Citations (302)
Number Name Date Kind
3472230 Fogarty Oct 1969 A
4619246 Molgaard-Nielsen et al. Oct 1986 A
4630609 Chin Dec 1986 A
4650466 Luther Mar 1987 A
4706671 Weinrib Nov 1987 A
4723549 Wholey et al. Feb 1988 A
4873978 Ginsburg Oct 1989 A
5108419 Reger Apr 1992 A
5192286 Phan et al. Mar 1993 A
5200248 Thompson et al. Apr 1993 A
5329923 Lundquist Jul 1994 A
5348545 Shani et al. Sep 1994 A
5381782 DeLaRama et al. Jan 1995 A
5395327 Lundquist et al. Mar 1995 A
5613980 Chauhan Mar 1997 A
5624430 Eton et al. Apr 1997 A
5662671 Barbut et al. Sep 1997 A
5680873 Berg et al. Oct 1997 A
5707389 Louw et al. Jan 1998 A
5766151 Valley et al. Jun 1998 A
5779716 Cano et al. Jul 1998 A
5814064 Daniel et al. Sep 1998 A
5827324 Cassell Oct 1998 A
5833650 Imran Nov 1998 A
5848964 Samuels Dec 1998 A
5897529 Ponzi Apr 1999 A
5897819 Miyata et al. Apr 1999 A
5910154 Tsugita et al. Jun 1999 A
5910364 Miyata et al. Jun 1999 A
5911734 Tsugita et al. Jun 1999 A
5935139 Bates Aug 1999 A
5980555 Barbut et al. Nov 1999 A
5989281 Barbut et al. Nov 1999 A
5993469 McKenzie et al. Nov 1999 A
6001118 Daniel et al. Dec 1999 A
6010522 Barbut et al. Jan 2000 A
6027520 Tsugita et al. Feb 2000 A
6042598 Tsugita et al. Mar 2000 A
6045547 Ren et al. Apr 2000 A
6051014 Jang Apr 2000 A
6080140 Swaminathan et al. Jun 2000 A
6083239 Addis Jul 2000 A
6096053 Bates Aug 2000 A
6099534 Bates Aug 2000 A
6120494 Jonkman Sep 2000 A
6126673 Kim et al. Oct 2000 A
6129739 Khosravi Oct 2000 A
6142987 Tsugita Nov 2000 A
6146396 Konya Nov 2000 A
6152946 Broome et al. Nov 2000 A
6171328 Addis Jan 2001 B1
6179851 Barbut et al. Jan 2001 B1
6179861 Khosravi et al. Jan 2001 B1
6203561 Ramee et al. Mar 2001 B1
6214026 Lepak et al. Apr 2001 B1
6235045 Barbut et al. May 2001 B1
6245087 Addis Jun 2001 B1
6245088 Lowery Jun 2001 B1
6245089 Daniel et al. Jun 2001 B1
6264663 Cano Jul 2001 B1
6270513 Tsugita et al. Aug 2001 B1
6277138 Levinson et al. Aug 2001 B1
6287321 Jang Sep 2001 B1
6290710 Cryer et al. Sep 2001 B1
6309399 Barbut et al. Oct 2001 B1
6325815 Kusleika et al. Dec 2001 B1
6336934 Gilson et al. Jan 2002 B1
6336116 Brooks et al. Feb 2002 B1
6361545 Macoviak et al. Mar 2002 B1
6364900 Heuser Apr 2002 B1
6371970 Khosravi Apr 2002 B1
6371971 Tsugita et al. Apr 2002 B1
6375628 Zadno-Azizi et al. Apr 2002 B1
6383174 Eder May 2002 B1
6383205 Samson May 2002 B1
6440120 Maahs Aug 2002 B1
6454799 Schreck Sep 2002 B1
6485502 Don Michael Nov 2002 B2
6499487 McKenzie et al. Dec 2002 B1
6517559 O'Connell Feb 2003 B1
6530939 Hopkins et al. Mar 2003 B1
6537297 Tsugita et al. Mar 2003 B2
6544279 Hopkins et al. Apr 2003 B1
6558356 Barbut May 2003 B2
6589263 Hopkins et al. Jul 2003 B1
6595983 Voda Jul 2003 B2
6605102 Mazzocchi Aug 2003 B1
6616679 Khosravi et al. Sep 2003 B1
6620148 Tsugita Sep 2003 B1
6620182 Khosravi et al. Sep 2003 B1
6648837 Kato et al. Nov 2003 B2
6663652 Daniel et al. Dec 2003 B2
6676682 Tsugita et al. Jan 2004 B1
6712834 Yassour et al. Mar 2004 B2
6712835 Mazzocchi Mar 2004 B2
6719717 Johnson et al. Apr 2004 B1
6726621 Suon et al. Apr 2004 B2
6726651 Robinson et al. Apr 2004 B1
6726701 Gilson Apr 2004 B2
6740061 Oslund May 2004 B1
6817999 Berube et al. Nov 2004 B2
6830579 Barbut Dec 2004 B2
6843798 Kusleika et al. Jan 2005 B2
6872216 Daniel Mar 2005 B2
6881194 Miyata et al. Apr 2005 B2
6887258 Denison May 2005 B2
6905490 Parodi Jun 2005 B2
6907298 Smits et al. Jun 2005 B2
6958074 Russell Oct 2005 B2
6969396 Krolik et al. Nov 2005 B2
7011094 Rapacki et al. Mar 2006 B2
7048752 Mazzocchi May 2006 B2
7094249 Broome Aug 2006 B1
7115134 Chambers Oct 2006 B2
7160255 Saadat Jan 2007 B2
7169161 Bonnette et al. Jan 2007 B2
7169165 Belef et al. Jan 2007 B2
7182757 Miyata et al. Feb 2007 B2
7214237 Don Michael May 2007 B2
7278974 Kato et al. Oct 2007 B2
7303575 Ogle Dec 2007 B2
7306618 Demond et al. Dec 2007 B2
7313445 McVenes et al. Dec 2007 B2
7323001 Clubb et al. Jan 2008 B2
7329278 Seguin et al. Feb 2008 B2
7399308 Borillo et al. Jul 2008 B2
7410491 Hopkins Aug 2008 B2
7493154 Bonner et al. Feb 2009 B2
7559925 Goldfarb et al. Jul 2009 B2
7572272 Denison et al. Aug 2009 B2
7621904 McFerran et al. Nov 2009 B2
7722634 Panetta et al. May 2010 B2
7766961 Patel et al. Aug 2010 B2
7918859 Katoh et al. Apr 2011 B2
7922732 Mazzocchi et al. Apr 2011 B2
7976562 Bressler et al. Jul 2011 B2
7998104 Chang Aug 2011 B2
8002790 Brady et al. Aug 2011 B2
8021351 Boldenow et al. Sep 2011 B2
8052713 Khosravi et al. Nov 2011 B2
8092483 Galdonik et al. Jan 2012 B2
8206412 Galdonik et al. Jun 2012 B2
8372108 Lashinski Feb 2013 B2
8382788 Galdonik Feb 2013 B2
8460335 Carpenter Jun 2013 B2
8518073 Lashinski Aug 2013 B2
8753370 Lashinski Jun 2014 B2
8876796 Fifer et al. Nov 2014 B2
8974489 Lashinski Mar 2015 B2
9017364 Fifer et al. Apr 2015 B2
9055997 Fifer et al. Jun 2015 B2
9259306 Fifer et al. Feb 2016 B2
9326843 Lee et al. May 2016 B2
9345565 Fifer et al. May 2016 B2
9480548 Carpenter Nov 2016 B2
9492264 Fifer et al. Nov 2016 B2
9566144 Purcell et al. Feb 2017 B2
9636205 Lee et al. May 2017 B2
9943395 Fifer et al. Apr 2018 B2
9980805 Fifer May 2018 B2
10130458 Lashinski Nov 2018 B2
20010041858 Ray et al. Nov 2001 A1
20020022858 Demond et al. Feb 2002 A1
20020026145 Bagaoisan et al. Feb 2002 A1
20020055767 Forde et al. May 2002 A1
20020068015 Polaschegg et al. Jun 2002 A1
20020077596 McKenzie et al. Jun 2002 A1
20020095170 Krolik et al. Jul 2002 A1
20020095172 Mazzocchi et al. Jul 2002 A1
20020123761 Barbut et al. Sep 2002 A1
20020161394 Macoviak et al. Oct 2002 A1
20020165571 Herbert et al. Nov 2002 A1
20020165573 Barbut Nov 2002 A1
20030100919 Hopkins et al. May 2003 A1
20030130684 Brady et al. Jul 2003 A1
20030144686 Martinez et al. Jul 2003 A1
20030171770 Kusleika et al. Sep 2003 A1
20030199960 Paskar Oct 2003 A1
20040002730 Denison et al. Jan 2004 A1
20040006370 Tsugita Jan 2004 A1
20040044350 Martin et al. Mar 2004 A1
20040044360 Lowe Mar 2004 A1
20040064092 Tsugita et al. Apr 2004 A1
20040093015 Ogle May 2004 A1
20040153117 Clubb Aug 2004 A1
20040167565 Beulke et al. Aug 2004 A1
20040193206 Gerberding Sep 2004 A1
20040215167 Belson Oct 2004 A1
20040215230 Frazier Oct 2004 A1
20040220611 Ogle Nov 2004 A1
20040225321 Krolik et al. Nov 2004 A1
20040230220 Osborne Nov 2004 A1
20040243175 Don Michael Dec 2004 A1
20040254601 Eskuri Dec 2004 A1
20040254602 Lehe et al. Dec 2004 A1
20050010285 Lambrecht et al. Jan 2005 A1
20050065397 Saadat et al. Mar 2005 A1
20050080356 Dapolito et al. Apr 2005 A1
20050085847 Galdonik et al. Apr 2005 A1
20050101987 Salahieh May 2005 A1
20050131449 Salahieh et al. Jun 2005 A1
20050137696 Salahieh Jun 2005 A1
20050177132 Lentz et al. Aug 2005 A1
20050209631 Galdonik et al. Sep 2005 A1
20050277976 Galdonik et al. Dec 2005 A1
20060015136 Besselink Jan 2006 A1
20060015138 Gertner Jan 2006 A1
20060030877 Martinez et al. Feb 2006 A1
20060041188 Dirusso et al. Feb 2006 A1
20060047301 Ogle Mar 2006 A1
20060089618 McFerran et al. Apr 2006 A1
20060089666 Linder et al. Apr 2006 A1
20060100658 Obana et al. May 2006 A1
20060100662 Daniel et al. May 2006 A1
20060129180 Tsugita et al. Jun 2006 A1
20060135961 Rosenman et al. Jun 2006 A1
20060136043 Cully et al. Jun 2006 A1
20060149350 Patel et al. Jul 2006 A1
20060161241 Barbut et al. Jul 2006 A1
20060200047 Galdonik et al. Sep 2006 A1
20060200191 Zadno-Azizi Sep 2006 A1
20060259066 Euteneuer Nov 2006 A1
20070005131 Taylor Jan 2007 A1
20070043259 Jaffe et al. Feb 2007 A1
20070060944 Boldenow et al. Mar 2007 A1
20070088244 Miller et al. Apr 2007 A1
20070088383 Pal et al. Apr 2007 A1
20070173878 Heuser Jul 2007 A1
20070191880 Cartier et al. Aug 2007 A1
20070208302 Webster et al. Sep 2007 A1
20070244504 Keegan et al. Oct 2007 A1
20080004687 Barbut Jan 2008 A1
20080033467 Miyamoto et al. Feb 2008 A1
20080058860 Demond et al. Mar 2008 A1
20080065145 Carpenter Mar 2008 A1
20080065147 Mazzocchi et al. Mar 2008 A1
20080086110 Galdonik et al. Apr 2008 A1
20080109088 Galdonik et al. May 2008 A1
20080125848 Kusleika et al. May 2008 A1
20080154153 Heuser Jun 2008 A1
20080172066 Galdonik et al. Jun 2008 A9
20080188884 Gilson et al. Aug 2008 A1
20080234722 Bonnette et al. Sep 2008 A1
20080262442 Carlin et al. Oct 2008 A1
20080300462 Intoccia et al. Dec 2008 A1
20090024072 Criado et al. Jan 2009 A1
20090024153 Don Michael Jan 2009 A1
20090069840 Hallisey Mar 2009 A1
20090198269 Hannes et al. Aug 2009 A1
20090203962 Miller et al. Aug 2009 A1
20090254172 Grewe Oct 2009 A1
20090287187 Legaspi et al. Nov 2009 A1
20090326575 Galdonik Dec 2009 A1
20100004633 Rothe et al. Jan 2010 A1
20100010476 Galdonik et al. Jan 2010 A1
20100063537 Ren et al. Mar 2010 A1
20100106182 Patel et al. Apr 2010 A1
20100179583 Carpenter et al. Jul 2010 A1
20100179584 Carpenter et al. Jul 2010 A1
20100179585 Carpenter et al. Jul 2010 A1
20100179647 Carpenter et al. Jul 2010 A1
20100185216 Garrison et al. Jul 2010 A1
20100185231 Lashinski Jul 2010 A1
20100191276 Lashinski Jul 2010 A1
20100211095 Carpenter Aug 2010 A1
20100228280 Groothius et al. Sep 2010 A1
20100312268 Belson Dec 2010 A1
20100324589 Carpenter et al. Dec 2010 A1
20110022076 Lashinski Jan 2011 A1
20110066221 White et al. Mar 2011 A1
20110282379 Lee et al. Nov 2011 A1
20120046739 von Oepen et al. Feb 2012 A1
20120095500 Heuser Apr 2012 A1
20120172020 Fifer et al. Jul 2012 A1
20120172915 Fifer et al. Jul 2012 A1
20120172916 Fifer et al. Jul 2012 A1
20120172917 Fifer et al. Jul 2012 A1
20120172919 Fifer et al. Jul 2012 A1
20120203265 Heuser Aug 2012 A1
20120289996 Lee et al. Nov 2012 A1
20130123835 Anderson et al. May 2013 A1
20130131714 Wang et al. May 2013 A1
20130231694 Lashinski Sep 2013 A1
20140052170 Heuser et al. Feb 2014 A1
20140094843 Heuser Apr 2014 A1
20140100597 Wang et al. Apr 2014 A1
20140243877 Lee et al. Aug 2014 A9
20140249567 Adams et al. Sep 2014 A1
20140282379 Bijani et al. Sep 2014 A1
20150039016 Naor et al. Feb 2015 A1
20150073533 Kassab et al. Mar 2015 A1
20150230910 Lashinski et al. Aug 2015 A1
20150335416 Fifer et al. Nov 2015 A1
20160058541 Schotzko et al. Mar 2016 A1
20160262864 Von Mangoldt et al. Sep 2016 A1
20160310255 Purcell et al. Oct 2016 A1
20170042658 Lee et al. Feb 2017 A1
20170112609 Purcell et al. Apr 2017 A1
20170181834 Fifer et al. Jun 2017 A1
20170202657 Lee et al. Jul 2017 A1
20180177582 Lashinski Jun 2018 A1
20180235742 Fields et al. Aug 2018 A1
Foreign Referenced Citations (39)
Number Date Country
10049812 Apr 2002 DE
1400257 Mar 2004 EP
1253871 Feb 2007 EP
2303384 Apr 2011 EP
2391303 Dec 2011 EP
2480165 Aug 2012 EP
2658476 Nov 2013 EP
2387427 Aug 2014 EP
2859864 Apr 2015 EP
2003505216 Feb 2003 JP
2003526451 Sep 2003 JP
2003290231 Oct 2003 JP
3535098 Jun 2004 JP
2006500187 Jan 2006 JP
2008511401 Apr 2008 JP
2008511401 Apr 2008 JP
2008515463 May 2008 JP
2008515463 May 2008 JP
2011525405 Sep 2011 JP
9923976 May 1999 WO
0021604 Apr 2000 WO
0108743 Feb 2001 WO
0167989 Sep 2001 WO
2004026175 Apr 2004 WO
2005118050 Dec 2005 WO
2006026371 Mar 2006 WO
2006076505 Jul 2006 WO
2008033845 Mar 2008 WO
2008100790 Aug 2008 WO
2008113857 Sep 2008 WO
2009032834 Mar 2009 WO
2010008451 Jan 2010 WO
2010081025 Jul 2010 WO
2010083527 Jul 2010 WO
2010088520 Aug 2010 WO
2011034718 Mar 2011 WO
2011017103 Oct 2011 WO
2012092377 Jul 2012 WO
2018156655 Aug 2018 WO
Non-Patent Literature Citations (15)
Entry
Internet Archive Wayback Machine; Fiber Innovative Technology: FIT Capabilities; downloaded from http://web.archive.org/web/20010217040848/http://www.fitfibers.com/capabilities.htm (Archived Feb. 17, 2001; printed on Dec. 12, 2016).
Internet Archive Wayback Machine; Fiber Innovative Technology: 4DG Fibers; downloaded from http://web.archive.org/web/20011030070010/http://fitfibers.com/4DG_Fibers.htm (Archived Oct. 30, 2001; printed on Dec. 12, 2016).
Internet Archive Wayback Machine; Fiber Innovative Technology: FIT Products; downloaded from http://web.archive.org/web/20010408003529/http://www.fitfibers.com/product.htm (Archived Apr. 8, 2001; printed on Dec. 12, 2016).
Final Office Action for U.S. Appl. No. 13/383,488 dated Mar. 4, 2014 in 14 pages.
International Search Report in Application No. PCT/US2010/043390 dated Apr. 8, 2011, in 11 pages.
Notice of Allowance for U.S. Appl. No. 12/844,420 dated Feb. 4, 2014, in 14 pages.
Notice of Allowance for U.S. Appl. No. 13/383,488 dated Oct. 30, 2014, in 10 pages.
Office Action for U.S. Appl. No. 12/844,420 dated Jul. 31, 2013, in 13 pages.
Office Action for U.S. Appl. No. 13/383,488 dated Sep. 5, 2013, in 18 pages.
Extended European Search Report for Appl. No. 10806888.3 dated Sep. 29, 2017 in 7 pages.
Lee et al: U.S. Appl. No. 12/871,708 entitled “intravascular Blood Filters and Methods of Use,” filed Aug. 30, 2010.
International Search Report in Application No. PCT/US2010/021417 dated Aug. 23, 2010, in 4 pages.
International Search Report in Application No. PCT/US2010/047166 dated Apr. 27, 2011, in 7 pages.
International Search Report in Application No. PCT/US2011/067598 dated May 10, 2012 in 45 pages.
International Preliminary of Patentability in application No. PCT/US2010/022590 dated Jan. 29, 20110 in 4 pages.
Related Publications (1)
Number Date Country
20190076232 A1 Mar 2019 US
Provisional Applications (1)
Number Date Country
61228703 Jul 2009 US
Continuations (2)
Number Date Country
Parent 14644083 Mar 2015 US
Child 16182807 US
Parent 13383488 US
Child 14644083 US